Melanoma Clinical Trial

MElanoma Research Lymph Node Prediction Implementation National_001

Summary

MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Newly diagnosed patients with invasive malignant melanoma of the skin (AJCC 8th edition staging guidelines) elected to undergo sentinel lymph node biopsy per the treating physician's recommendation.
Male or female, age ≥18 years.

Exclusion Criteria:

Full primary melanoma pathology report unavailable.
Documented clinically apparent nodal metastases at diagnosis.
Distant metastatic disease (M1a,b,c,d) clinically present at primary diagnosis
Any prior or concurrent primary invasive melanoma mapping to the same draining lymph node basin(s).
Documented history of another (prior or concurrent) primary invasive melanoma of T1b or greater at any site within the last 5 years.
Previous surgery in or radiation therapy to the draining lymph node basin(s) of the current primary melanoma.
Ocular, vulvar, perianal or mucosal melanomas or melanocytic tumors of uncertain malignant potential (MELTUMP) or atypical Spitz tumors.

Study is for people with:

Melanoma

Estimated Enrollment:

2340

Study ID:

NCT04759781

Recruitment Status:

Recruiting

Sponsor:

SkylineDx

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

Moffitt Cancer Center
Tampa Florida, 33612, United States More Info
Vernon K. Sondak, MD
Contact
Emory University School of Medicine
Atlanta Georgia, 30322, United States More Info
Michael C. Lowe, MD/MA
Contact
University of Kentucky
Lexington Kentucky, 40506, United States More Info
Erin E. Burke, MD
Contact
University of Louisville
Louisville Kentucky, 40292, United States More Info
Michael E. Egger, MD/MPH
Contact
University of Michigan
Ann Arbor Michigan, 48109, United States More Info
Christina V. Angeles, MD
Contact
Mayo Clinic
Rochester Minnesota, 55905, United States More Info
Tina J. Hieken, MD
Contact
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States More Info
Edmund K. Bartlett, MD
Contact
Duke University
Durham North Carolina, 27705, United States More Info
Georgia M. Beasley, MD, MHSc
Contact
Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States More Info
John R. Hyngstrom, MD
Contact

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

2340

Study ID:

NCT04759781

Recruitment Status:

Recruiting

Sponsor:


SkylineDx

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.